Shangya Technology Co., Ltd. (TPEX:6130)
23.00
+0.15 (0.66%)
Oct 8, 2026, 1:30 PM CST
Shangya Technology Revenue
Shangya Technology had revenue of 49.63M TWD in the quarter ending June 30, 2026, with 28.21% growth. This brings the company's revenue in the last twelve months to 165.30M, down -6.28% year-over-year. In the year 2025, Shangya Technology had annual revenue of 154.74M, down -20.79%. That makes Shangya Technology the 39,822nd largest company in the world by revenue and 2,067th in Taiwan.
Revenue (ttm)
165.30M
Revenue Growth
-6.28%
P/S Ratio
6.44
Revenue / Employee
5.33M
Employees
31
Market Cap
1.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 154.74M | -40.62M | -20.79% |
| Dec 31, 2024 | 195.35M | -35.76M | -15.47% |
| Dec 31, 2023 | 231.12M | 145.95M | 171.36% |
| Dec 31, 2022 | 85.17M | -18.65M | -17.96% |
| Dec 31, 2021 | 103.82M | -34.06M | -24.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 20.75B |
| Rossmax International | 3.78B |
| Prince Pharmaceutical | 1.22B |
| Concord Medical | 1.04B |
| Genetics Generation Advancement | 614.42M |
| Ttbio | 433.42M |
| Puriblood Medical | 80.54M |
| Caliway Biopharmaceuticals | 29.39M |